Scientists track tumor evolution under immune attack in tiny study
NCT ID NCT02724488
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how tumors evolve when treated with immune checkpoint inhibitors, a type of immunotherapy. Researchers will take blood samples and tumor biopsies from 14 people with advanced head and neck cancer or melanoma to track genetic changes. The goal is to understand why some tumors become resistant to treatment, not to test a new drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors understand why some tumors stop responding to immune therapies, potentially guiding future treatment strategies.
What could go wrong
This is a very small, early-stage observational study with only 14 participants, so results may not apply broadly. It is designed to gather knowledge, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.